Uterine Fibroid study: Ryeqo treatment
Official title The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters
ClinicalTrials.gov ID: NCT07173127
What this study is testing
What is Ryeqo treatment?
an investigational oral medication being studied as a potential treatment for uterine fibroids is designed to block GnRH receptors and lower estrogen and progesterone levels while providing low‑dose hormone add‑back
Also referred to as Relugolix combination (relugolix with estradiol and norethindrone acetate).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see how Ryeqo changes blood markers that indicate risk of blood clots, so doctors can better match treatment to each woman’s risk.
- Who it's for
- Women with uterine fibroids (and possibly endometriosis) who can safely take Ryeqo.
- What's involved
- Participants will start Ryeqo, have a pregnancy test and blood draw at the first visit, fill out a questionnaire, and then return after 3 months for another blood draw and questionnaire.
- Time commitment
- The study lasts 3 months and requires two clinic visits, one at the start and one 3 months later.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only. Healthy volunteers may be eligible.
You may be able to join if
- Women consulting at the DFEA of the HUG, who are prescribed Ryeqo® for a qualified medical condition
- Age ≥ 18 years
You likely can't join if
- Unable to speak and/or read French
- Having used either an oestro-progestin pill (oral, patch or vaginal ring) or oral estrogens in the past 3 months, or DMPA or nomegestrol acetate
- Women not having given their consent to participate in the study
The study team makes the final eligibility decision.
Where it is enrolling
- Geneva, Canton of Geneva, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Geneva, Canton of Geneva, Switzerland. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.